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SUMMARY
Tumour necrosis factor-a (TNF-a) and interleukin-1/? (IL-1 /?) are pro-inflammatory cytokines 
. that play an important role in severe infections, whereas IL-1 receptor antagonist (IL-lra) and 
IL-10 are anti-inflammatory cytokines that counteract their effects. Chlorpromazine and dexame­
thasone protect mice against lethal endotoxaemia by decreasing circulating concentrations of 
TNF-a and IL-1/?. We investigated whether administration of chlorpromazine or dexamethasone 
to human volunteers is able to modulate the lipopolysaccharide (LPS)-stimulated cytokine 
production capacity in whole blood. Blood samples were taken before and several tiine-points 
after medication. Circulating cytokine concentrations were low in all samples. LPS-induced TNF- 
a and IL-1/? production in whole blood was inhibited by dexamethasone treatment, while 
chlorpromazine had no effect. When peripheral blood mononuclear cells were stimulated In vitro 
with LPS, the addition of chlorpromazine (1-100 ng/ml) had no modulatory action on TNF-a, 
IL-1 ft IL-lra or IL-10 synthesis. The chlorpromazine concentrations measured in circulation of 
volunteers were eight to 40 times lower than the concentrations shown to be effective in mice. In 
conclusion, chlorpromazine inhibits TNF-a and IL-1/? production in mice at concentrations that 
cannot be reached in humans, thus precluding its usage in clinical anti-cytokine strategies. In 
contrast, dexamethasone is an effective inhibitor of pro-inflammatory cytokine production.
INTRODUCTION
The pro-inflammatory cytokines interleukin-1/? (IL-1/?) and 
tumour necrosis factor-a (TNF-a) play an important role in 
the pathogenesis of sepsis.1 Blocking TNF improves survival 
in mice receiving a lethal endotoxin challenge2 and in baboons 
challenged with an injection of Escherichia coli bacteria,3 while 
administration of IL-1 receptor antagonist (IL-lra), a nat­
urally occurring antagonist of IL-1, has been shown to prevent 
experimental septic shock.4 Therefore, pharmacological agents 
that inhibit TNF-a and IL-1/? synthesis may prove beneficial 
in the treatment of severe infections.
Glucocorticoids are important anti-inflammatory agents. 
This effect is partly due to attenuation of the production of 
pro-inflammatory cytokines. Dexamethasone suppresses 
cytokine production by lipopolysaccharide (LPS)-stimulated 
human monocytes,5,6 and adrenalectomy sensitizes mice to the 
lethal effects of IL-1 and TNF.7 In lethal endotoxaemia, 
administration of dexamethasone was able to inhibit cytokine 
production and to increase survival.8,9 In healthy volunteers,
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glucocorticoids attenuated TNF production and the haemo- 
dynamic response when given immediately before LPS.10
Chlorpromazine, a phenothiazine derivative, is also able 
to protect mice against the effects of endotoxin through 
attenuation of serum levels of cytokines.8,9,11 In vitro, chlorpro­
mazine is able to inhibit TNF-a synthesis by human mono­
cytes.12 In addition, recent studies reported stimulatory effects 
of chlorpromazine on the production of IL-10, an anti­
inflammatory cytokine able to inhibit the production of TNF- 
a and IL-1 f t13,14 Thus, chlorpromazine could be a useful drug 
for cytokine modulation in humans.
The aim of this study was to investigate the capacity of 
chlorpromazine to modulate cytokine synthesis in humans, by 
administration of chlorpromazine to healthy volunteers and 
measurement of the ex vivo LPS-stimulated production of 
TNF-a, IL-1/?, IL-lra and IL-10. The effect of chlorpromazine 
was compared to that of dexamethasone.
MATERIALS AND METHODS
Ex vivo studies in humans
Eighteen healthy volunteers (five females and 13 males, mean 
age 24 years, range 19-36 years) participated in the study, 
after giving written informed consent. The study was approved 
by the ethics committee of the University Hospital Nijmegen.
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The volunteers refrained from heavy exercise, since this was 
shown to modulate cytokine production,15 and did not use 
any medication. They were randomized to receive chlorproma- 
zine (25 mg t.i.d.; Brocacef, Maarssen, the Netherlands), 
dexamethasone [1.5 mg three times a day (t.i.d.); Genpharma, 
Maarssen, the Netherlands], or placebo at 8-h intervals. Blood 
samples were drawn 5 hr before treatment and 1, 4 and 25 hr 
after taking the third dose. All samples were drawn at 9 a.m. 
while subjects fasted, except the third sample which was 
obtained at noon after a small standard meal.
Ex vivo whole blood production assay was performed as 
desciibed elsewhere,16 with minor modifications. Briefly, blood 
was collected in one 4-ml and two 2-ml EDTA tubes 
(Vacutainer systems, Beet on Dickinson, Rutherford, NJ). The 
first tube was processed immediately and used for measuring 
circulating levels of TNF-a, IL-1/?, IL-lra and IL-10. In the 
other tubes, ex vivo cytokine production was determined; one 
tube was incubated at 37° with lipopolysaccharide (LPS; 
10jug/ml; Escherichia coil 055:B5; Sigma Chemical Co., St 
Louis, MO) for 24 hr and the other without additional stimuli. 
After incubation, the tubes were centrifuged at 10 000 g for
10 min. The plasma was separated and centrifuged at 15000 
g for 5 min to obtain platelet-poor plasma. Blood for chlorpro- 
mazine measurement was drawn into 10-ml tubes (Venoject II, 
Terumo Europe, Leuven, Belgium), and plasma obtained by 
centrifugation (10 min, 10 000 g). Aliquots were stored at 
—20° until assay.
Three of the volunteers receiving chlorpromazine took part 
in an additional study to assess whether chlorpromazine 
administration in vivo can modify cytokine production by 
isolated peripheral blood mononuclear cells (PBMC). 
Chlorpromazine was administered as described above and 
blood was collected 5 hr before the treatment was started and
1 hr after the third dose. Isolation of PBMC was performed 
as described elsewhere,17 with minor modifications. Briefly, 
venous blood was drawn into 10-ml EDTA tubes (Monoject, 
’s-Hertogenbosch, the Netherlands). The PBMC fraction was 
obtained by density centrifugation of blood (diluted 1:1 in 
pyrogen-free saline) over Ficoll-Paque (Pharmacia Biotech 
AB, Uppsala, Sweden). PBMC were washed twice in saline, 
and suspended in culture medium (RPMI-1640 Dutch modifi­
cation, ICN Biomedicals Inc., Costa Mesa) supplemented with 
human serum 5%, gentamicine 1%, L-glutamine 1%, pyruvate 
1%. The cells were counted in a Coulter counter (Coulter 
Electronics, Mijdrecht, the Netherlands) and the number was 
adjusted to 5 x 106 cells/ml. One hundred microlitres were 
incubated in 96-well plates (Greiner B.V., Alp hen a/d Rijn, 
the Netherlands) with LPS (final concentration 1 ng/ml) for 
24 hr at 37°. After 24 hr of incubation the supernatants were 
frozen (—20°) until assay.
In vitro effect o f chlorpromazine
In order to assess the effect of chlorpromazine without inter­
ference of in vivo pharmacokinetics, the in vitro effect of 
chlorpromazine on cytokine production was investigated. 
Whole blood or PBMC were obtained from seven volunteers 
as described above. All volunteers were healthy and received 
no treatment. LPS stimulation of PBMC or whole blood 
cultures was performed for 24 hr at 37°, as described above, 
in the presence or absence of chlorpromazine ( l - 10n 
Additionally, the effect of chlorpromazine at a concentration
of 100 ng/ml on cytokine production was tested in LPS- 
stimulated PBMC from three volunteers. Samples were stored 
at —20° until assay.
Studies in mice
Mice (C57B1/6J mice, 8 weeks old, weight 20-25 g) were given 
chlorpromazine (4 mg/kg) in pyrogen-free saline by intraperi- 
toneal (i.p.) injection, 30 min before challenge with LPS 
(30/ig/kg intraperitoneally). This dose has been shown to be 
optimal for the chlorpromazine-induced protection in lethal 
endotoxaemia.11 After 90 min, the mice were anaesthetized 
with ether and bled from the retroorbital plexus. Blood was 
pooled into two 10-ml tubes (Venoject) and serum was stored 
at —20° until measurement of the plasma concentration of 
chlorpromazine.
Cytokine measurements
TNF-a, IL-1/? and IL-lra concentration were determined by 
radioimmunoassay as described elsewhere.13 IL-10 concen­
trations were determined by a commercially available enzyme- 
linked immunosorbent assay (ELISA) kit (CLB, Amsterdam, 
the Netherlands), according to the instructions of the manufac­
turer. In order to correct for spontaneous cytokine release, 
the net production was calculated by subtracting the values in 
the unstimulated samples from the concentration obtained 
after LPS stimulation.
Chlorpromazine measurement
Concentrations of chlorpromazine were measured at the 
Department of Pharmacy, St Elisabeth Hospital Venray, the 
Netherlands, with one-step extraction followed by high- 
pressure liquid chromatography. In short, 1 ml of serum was 
mixed with 0*4 mi of carbonic buffer (pH 9*4), 2-0 ml hep­
tane : iso-amyl alcohol (985:15), and 50 /¿I of Northiaden 
50 /ig/1. After centrifugation, the heptane phase was transferred 
and dried at 60°. Chromatography was performed on a 
Spherisorb S5W with guard column. The mobile phase con­
sisted of MeOH/Acetonitril/25% ammonia (20/280/1), the flow 
was l'4ml/min and ultra-violet light was used for detection.
Statistical analysis
Data are shown as mean±SEM. Differences between curves 
were tested using a n o v a  for repeated measures. Differences at 
time-points between more than two groups were tested with 
a n o v a . Differences in production of cytokines between drug 
and placebo were analysed using non-parametric Wilcoxon 
test. Results were considered statistically significant at P <0-05.
RESULTS
Effect of orally applied chlorpromazine and dexamethasone on 
cytokine production
i
Five of the volunteers reported side-effects of the medication. 
One of the volunteers receiving placebo felt dizzy. Four subjects 
taking chlorpromazine experienced drowsiness and one 
reported abdominal pain. Circulating concentrations of TNF-
a, IL-1/?, IL-lra and IL-10 were very low and in the normal 
range in all samples, and were not altered by the treatment 
with either of the two drugs (range TNF-a< 40-100 pg/ml; 
IL-1/? <20-90 pg/ml; IL-lra 80-400 pg/ml; IL-10 in all 
samples <38 pg/ml).
© 1997 Blackwell Science Ltd, Immunology, 91, 548-552
550 M . W. P . B le e k e r  et al.
Chlorpromazine treatment did not influence either the 
TNF-a or the IL-l/i production capacity in whole blood at 
any of the time-points tested (Fig, la, b), Neither of the drugs 
had any effect on IL-lra synthesis (Fig. lc). Dexamethasone 
significantly inhibited ex vivo whole blood production of TNF- 
a both 1 and 4 hr (P<0-01 ), but not 24 hr, after last adminis­
tration (Fig, la). Synthesis of IL-l/i was inhibited 1 hr 
(P<0-05), but not 4 and 24hr, after the last dexamethasone 
dose (Fig. lb). IL-10 concentrations with and without LPS- 
stimulation were very low and not stimulated by treatment 
with chlorpromazine or dexamethasone (data not shown).
Since chlorpromazine had no effect on cytokine production 
in whole blood cultures, we investigated whether this could be 
due to interference by the various cell types present in circu­
lation, or other plasma factors. The LPS-stimulated cytokine 
production of PBMC isolated from volunteers 1 hr after the 
last dose of chlorpromazine did not differ from their cytokine 
production capacity 5 hr before the start of the treatment 
(data not shown), suggesting that interference of plasma
—4 1 4
Time after treatment (hr)
Placebo - O  DEX
25
CP2
Figure 1. Dexamethasone (DEX), but not chlorpromazine (CPZ) 
treatment, significantly inhibited production of TNF-a (a) and IL-1/? 
(b) by LPS-stimulated whole blood cultures of human volunteers. 
Neither dexamethasone nor chlorpromazine treatment had any effect 
on IL-lra production (c).
factors with chlorpromazine in the whole blood assay was not 
responsible for the lack of effect of the drug.
Circulating concentrations of chlorpromazine
The serum concentrations of chlorpromazine in human volun­
teers were 2*5 ±0*3 ng/ml at 1 hr, 1*5 ±0*4 at 3 hr and 1*2 ±0*3 
at 25 hr after the last administration of chlorpromazine. In 
mice, i.p. treatment with 4 mg/kg chlorpromazine, which was 
shown to inhibit cytokine production by us and by others,8,11 
resulted in circulating chlorpromazine concentrations of 
41-0 ±3*0 ng/ml at 90 min after infection, i.e. 8-40 times higher 
than the concentrations in human volunteers.
In vitro effects of chlorpromazine
The effect of in vitro addition of chlorpromazine to LPS- 
stimulated PBMC and whole blood cultures was studied, 
Chlorpromazine concentrations that can be reached by oral 
administration of the drug in humans (1 and 10 ng/ml) were 
used. At these concentrations, there was no effect on cytokine 
production by LPS-stimulated PBMC (Fig. 2) or whole blood 
cultures (data not shown). Moreover, in an additional 
experiment, the chlorpromazine concentration of 100 ng/ml 
(20-times higher than the maximum chlorpromazine concen­
tration measured in volunteers) was also not effective for 
modulation of LPS-stimulated cytokine production by PBMC, 
when compared with non-treated cells (TNF-a, 0-9 ± 0-5 versus 
1*1 ±0-7 ng/ml; IL-1/?, 2-4±0-7 versus 2*3±0-5 ng/ml; IL-lra, 
9-7 ± 1*6 versus 12*9 ±4*4 ng/ml; IL-10, 0*3 ±0*15 versus 
0-4±0*1 ng/ml; P>0-05 for all cytokines).
DISCUSSION
The results of the present study show that chlorpromazine 
administered in vivo to human volunteers does not inhibit the 
production of TNF-a, IL-1/? and IL-lra, and has no stimu­
latory effect on IL-10 synthesis. In contrast, dexamethasone 
has a potent inhibitory action on TNF-a and IL-1 fi pro­
duction capacity.
The inhibiting effect of dexamethasone on pro- 
inflammatory cytokine production has been shown both in 
vitro5,6 and in human volunteers.10 The mechanism by which 
dexamethasone inhibits cytokine synthesis involves transcrip­
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Figure 2. Chlorpromazine (CPZ) had no effect on LPS-stimulated 
cytokine production capacity by isolated human PBMC in vitro.
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transcription factor NF-kB, blocking its translocation to the 
nucleus and thus markedly reducing cytokine synthesis.18 Our 
results show a marked inhibition of TNF-a and IL-1 /? synthesis 
in LPS-stimulated whole blood cultures of volunteers treated 
with dexamethasone. TNF-a production was diminished at 
both 1 and 4 hr after the last administered dose. IL-1/? 
production was significantly inhibited only after 1 hr, although 
a tendency of a decreased IL-1/? production was also seen 4 hr 
after the last administration of dexamethasone. In contrast, 
IL-lra production was not affected by dexamethasone treat­
ment. These data are corroborated by the results obtained by 
Santos et al.19 in an in vivo study in human volunteers. In 
contrast, recent studies have shown an inhibitory effect of 
hypercortisolaemia on IL-lra response after LPS in vivo20 and 
in vitro.21
In the present study, administration of chlorpromazine to 
human volunteers had no inhibitory action on the LPS- 
stimulated cytokine production in whole blood. No effect on 
synthesis of cytokines by PBMC was observed either, arguing 
against interference of chlorpromazine with plasma factors in 
the whole blood culture assay. These results are in accordance 
with the study of Martinez et a l ,22 who have also failed to 
demonstrate an inhibitory effect of chlorpromazine on IL-1 
production by human mononuclear cells. In contrast, several 
experimental studies in animals have shown that chlorpromaz­
ine protected animals from lethal endotoxaemia by inhibition 
of LPS-induced pro-inflammatory cytokine response8,9,11,23 
and stimulation of the anti-inflammatory cytokine IL-10.13,14 
A major difference between our study and the above-mentioned 
reports is the chlorpromazine concentrations in the circulation 
of the human volunteers, which was eight to 40 times lower 
than the concentrations observed in mice. In vitro studies 
performed on human monocytes have shown inhibitory effects 
of chlorpromazine on cytokine mRNA expression24 or pro­
duction.12 However, the chlorpromazine concentrations used 
in these studies were more than 100 times higher than the 
chlorpromazine circulating concentrations we measured in the 
volunteers receiving the drug.
The lack of effect of chlorpromazine in our study cannot 
be completely attributed to differences in plasma concen­
trations between mice and humans, because the concentrations 
used by Martinez et a l22 and the lOOng/ml chlorpromazine 
concentration used in vitro in some of our experiments were 
higher than the concentrations recorded in mice, while still 
having no effect on cytokine production by human PBMC. In 
this respect, it should be mentioned that as many as 10 or 12 
metabolites of chlorpromazine occur in circulation in appreci­
able quantities, many being active.25 Differences in the kinetics 
of chlorpromazine and in the drug metabolites in mice and 
humans may be also responsible for some of the differences 
observed.
In conclusion, in contrast with dexamethasone, which has 
a potent inhibitory effect on cytokine synthesis, administration 
of chlorpromazine did not influence LPS-stimulated cytokine 
production capacity in whole blood or PBMC of human 
volunteers, thus precluding its direct usage in clinical strategies
aimed to inhibit TNF-a and IL-1/?.
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